Women’s health news now includes a September FDA update on estrogen patch availability, a new review of testosterone use in menopause, and recent research on blood pressure care after childbirth. Cervical cancer prevention has also changed, with approved HPV self-collection options that can make screening more accessible for eligible patients.
These developments raise practical questions for women in the United States. Can a pharmacist help when a hormone patch is unavailable? Does a home HPV test replace an office visit? What follow-up matters after pregnancy-related hypertension? The answers depend on the treatment, the evidence, and each woman’s medical history.
Estrogen patch access is a current menopause care issue
On September 3, 2026, the FDA said it was working with all six manufacturers of estradiol transdermal patches to increase supply. Some patients had reported difficulty obtaining their usual product as demand grew. The agency said patches remained available, although access could vary by brand, pharmacy, and location.
The latest update on estradiol patch availability also reported that the supply of FDA-approved patches had nearly doubled over the previous year. Manufacturers were adding shifts, equipment, and production capacity. Larger expansions can take time because patches require specialized manufacturing.
Women who cannot find their usual patch should contact their pharmacist and prescriber. A pharmacist may locate an appropriate substitute, and a clinician can review other available treatment options. Changing the dose, stretching out treatment, or switching products without guidance can disrupt a prescribed care plan.
Hormone therapy labels changed, but individual risks still matter
The supply issue follows changes in how menopause hormone therapy risks appear on drug labels. On February 12, 2026, the FDA approved revised labeling for an initial group of six products. Statements about cardiovascular disease, breast cancer, and probable dementia were removed from their boxed warnings.
A boxed warning is the most prominent prescription drug safety warning. Its removal does not establish that a medicine has no risks. The updated hormone therapy labeling information retains cardiovascular and breast cancer warnings elsewhere for systemic products. The endometrial cancer boxed warning also remains for systemic estrogen-only products.
Treatment choice depends on symptoms, medical history, and whether the uterus is present. Systemic therapy can treat hot flashes and night sweats. Local vaginal estrogen treats vaginal symptoms. Women with a uterus generally need a progestogen alongside systemic estrogen to protect the uterine lining. Nonhormonal options are also available.
The revised approach includes consideration of systemic therapy for moderate to severe hot flashes in women younger than 60 or within 10 years of menopause. That is a factor in a clinical decision, not an automatic recommendation for everyone in that group.
Testosterone research has new attention in menopause care
The FDA held a public workshop on testosterone use in menopausal women on September 17, 2026. The discussion addressed growing off-label use and gaps in evidence about sexual function, mood, cognition, muscle and bone health, and long-term safety.
The recent FDA testosterone workshop identified particular uncertainty about cardiovascular and breast cancer risks over time. The public comment deadline was October 19, 2026. A workshop gathers evidence and research priorities; it does not itself approve a treatment.
September reporting on testosterone treatment for women confirmed that no FDA-approved product was available specifically for women. Evidence has focused on selected postmenopausal women with hypoactive sexual desire disorder, or persistently low desire that causes distress. Claims about treating general fatigue, poor concentration, or loss of muscle strength need separate evidence.
A low laboratory value alone does not explain every symptom. If an unfamiliar term appears in a report or health story, you can use the HealthWavy AI health assistant to ask general questions before an appointment. Diagnosis and hormone prescribing still require a qualified clinician.
Menopause research now includes sleep, mood, and long-term health
Menopause care is broader than treatment for hot flashes. The NIH’s April 15–17, 2026 workshop examined health during the menopausal transition, including symptoms and gaps in the research.
The current menopause research review had an independent panel draft report open for public comment through October 30, 2026. The report was still a draft at the time of this update.
Researchers are examining sleep, sexual health, mood, cholesterol, blood pressure, and bone density. These concerns can overlap, but they do not necessarily share one cause or one treatment. Age, medications, existing conditions, and daily circumstances also affect health during midlife.
At an appointment, describe the problem that affects your day most. Repeated night waking, pain with sex, and frequent hot flashes may need different approaches. A symptom record can help make that conversation more specific.
Cervical cancer screening now includes HPV self-collection
The American Cancer Society updated its cervical screening guideline on December 4, 2025. The current guidance includes self-collected vaginal samples for HPV testing, while samples collected from the cervix by a healthcare professional remain the preferred option.
Under the current cervical cancer screening guideline, average-risk individuals with a cervix start screening at age 25 and continue through at least age 65. The interval depends on the test and previous results.
| Screening option under ACS guidance | Routine interval after a normal result |
|---|---|
| Primary HPV test with a clinician-collected cervical sample | Every 5 years |
| HPV test with an approved self-collected vaginal sample | Every 3 years |
| HPV and Pap tests together, called co-testing | Every 5 years |
| Pap test alone when other approaches are unavailable | Every 3 years |
These are ACS recommendations. Other U.S. organizations use different starting ages and testing approaches. A clinician should confirm which schedule applies to your history.
What a self-collected HPV test can and cannot do
Self-collection allows an eligible patient to take a vaginal sample with an approved device. Depending on the available test, collection may occur privately in a clinic or at home. A healthcare provider must still order it, and access to home collection remains limited.
The HPV self-collection options may help patients who experience discomfort or anxiety during a pelvic exam. They do not replace all gynecologic care. A positive result usually requires an office visit and a clinician-collected cervical sample for further evaluation.
Women with previous cervical precancer, cervical cancer, immune suppression, or other high-risk factors need an individual plan. Unusual bleeding or pelvic symptoms also require assessment, even when routine screening is up to date.
Breast screening recommendations depend on personal risk
The CDC’s breast cancer screening information, reviewed on September 22, 2026, states that the USPSTF recommends a mammogram every two years for average-risk women ages 40 through 74. This remains the current Task Force recommendation; it was originally issued in April 2024.
The current mammogram recommendations distinguish routine screening from care for women at higher risk. Genetic risk, previous breast cancer, or other significant medical history can change the plan. A clinician may recommend additional imaging or a different schedule.
Screening checks for cancer before symptoms appear. A new lump, nipple change, or another concerning breast symptom deserves assessment without waiting for the next scheduled mammogram.
Follow-up matters as much as the first test. An abnormal mammogram does not automatically mean cancer, but it may require further imaging or a biopsy. Ask who will arrange that next step and when you should expect it.
New postpartum research supports longer follow-up for blood pressure
A randomized clinical trial published in JAMA Network Open on August 7, 2026, studied 140 postpartum women with pregnancy-related hypertensive disorders and relevant ongoing blood pressure concerns. All had completed an initial remote blood pressure monitoring program.
The recent postpartum blood pressure trial compared standard care with an intervention that combined self-measured blood pressure, telephone health coaching, and help coordinating primary care. Within the first postpartum year, 71.0% of participants with available outcome data in the intervention group attended a primary care visit, compared with 39.1% in the control group.
Blood pressure control also improved. This small, single-site trial did not establish that an app alone produces the same benefit.
The practical message is that pregnancy-related hypertension may need care beyond the early postpartum visit. The HealthWavy health app can help keep blood pressure readings, symptoms, medication records, and appointment notes together. Those records can support a conversation with your care team, but they do not replace clinical monitoring or treatment.
Symptoms after childbirth that need urgent attention
Serious pregnancy-related complications can occur during pregnancy and up to one year after delivery. The urgent maternal warning signs include a severe or worsening headache, vision changes, trouble breathing, chest pain, severe abdominal pain, fever of 100.4°F or higher, and heavy bleeding after pregnancy.
Seek immediate medical care for these symptoms. Thoughts of harming yourself or your baby also require immediate help. Call 911 in a life-threatening emergency, and tell the medical team if you have been pregnant within the past year.
PCOS and pelvic pain need care beyond a symptom checklist
PCOS can affect menstrual cycles, skin, fertility, and metabolic health. The NICHD’s current information, reviewed in July 2026, describes possible symptoms such as irregular periods, increased facial or body hair, acne, and insulin resistance.
The current information on PCOS makes clear that care can involve several aspects of health. An assessment should consider the symptoms, other possible causes, and the patient’s priorities, including whether pregnancy is a goal.
Endometriosis is a separate condition in which tissue similar to the uterine lining grows outside the uterus. Pain and fertility problems are common concerns. Persistent pelvic pain or menstrual changes should not be diagnosed from an online checklist alone.
If symptoms interfere with work, sleep, or daily activities, start a medical conversation. You can use HealthWavy’s doctor finder to begin a local search, then confirm the clinician’s services, credentials, insurance participation, and availability directly with the practice.
Autoimmune research covers health across a woman’s life
Autoimmune conditions involve the immune system attacking healthy tissue. They can affect joints, skin, glands, and internal organs. Several are more common among women, although the pattern varies by disease.
The NIH autoimmune disease research strategy for 2026–2030 addresses gaps in a group of conditions that can develop at different life stages. The plan was launched in July 2025 and remains relevant to current research priorities.
A research strategy does not create a new treatment protocol by itself. Women with an autoimmune diagnosis still need condition-specific care, especially when they plan pregnancy or consider changes to hormone treatment.
Mental health and bone health belong in routine care
Depression can develop during pregnancy, after childbirth, and during perimenopause. Persistent low mood, loss of interest, changes in sleep or appetite, and difficulty concentrating can deserve medical attention. Hormonal changes may contribute, but they are not the only possible cause.
The mental health guidance for women explains that treatment may involve therapy, medication, or both. Symptoms present most of the day, nearly every day, for at least two weeks warrant a conversation with a provider. Severe symptoms deserve help sooner. In the United States, call or text 988 for a mental health crisis, or 911 for immediate danger.
Bone health also needs an individual assessment. The current osteoporosis screening guidance recommends screening for women age 65 and older and for postmenopausal women younger than 65 who are at increased risk after clinical assessment. A DXA scan measures bone density.
Taking a supplement does not tell you whether your bones are weak. HealthWavy’s guide to calcium supplements for bone health covers food intake, daily needs, and safety questions to discuss with a clinician or dietitian.
Screening costs and access can affect the next step
Insurance, transportation, specialist availability, and medication access can determine whether someone receives recommended care. These barriers matter when a test is due or a prescription cannot be filled.
The free or low-cost breast and cervical screening program helps eligible women with low incomes who lack adequate insurance. Local programs can explain eligibility, diagnostic services, and patient navigation.
Ask about coverage for the exact service you need. Routine screening, diagnostic imaging, and a biopsy may have different costs. Before leaving a visit, confirm how you will receive results and who will contact you if follow-up is necessary.
Turn a health update into a useful medical question
The newest headline is not always the most relevant information for your care. An approved label change, a clinical trial, and a public research workshop answer different questions. A study also needs to be read in light of its participants, size, duration, and limitations.
Before changing a health routine, ask:
- Does this update apply to my age, symptoms, and medical history?
- Is it an approved change, a final guideline, or research still under review?
- What benefits and risks were measured?
- What should I discuss at my next appointment?
The September menopause updates and August postpartum trial add useful information to current women’s health care. Personal decisions still need the full context: symptoms, previous results, medication history, access to care, and the plan agreed with a clinician.
